Detail
Článek
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Blinatumomab overcomes poor prognostic impact of measurable residual disease in pediatric high-risk first relapse B-cell precursor acute lymphoblastic leukemia

F. Locatelli, C. Eckert, O. Hrusak, B. Buldini, M. Sartor, G. Zugmaier, Y. Zeng, D. Pilankar, J. Morris, A. von Stackelberg

. 2022 ; 69 (8) : e29715. [pub] 20220428

Jazyk angličtina Země Spojené státy americké

Typ dokumentu klinické zkoušky, fáze III, časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc22017817

BACKGROUND: Blinatumomab, a CD3/CD19 BiTE® (bispecific T cell engager) molecule, was superior to high-risk third course consolidation chemotherapy (HC3) in prolonging event-free survival (EFS) in children with high-risk first relapse B-cell precursor acute lymphoblastic leukemia (B-ALL). Here, we report results from a post hoc measurable residual disease (MRD) analysis of this phase 3 study (NCT02393859). PROCEDURE: Children >28 days and <18 years with high-risk first-relapse B-ALL in cytomorphological complete remission (M1 marrow, <5% blasts) or with M2 marrow (≥5% and <25% blasts) after induction and two cycles of high-risk consolidation chemotherapy (baseline) were enrolled in this trial. Patients received one cycle of blinatumomab (15 μg/m2 /day, 4 weeks, continuous intravenous infusion) or HC3. The primary endpoint was EFS. In this post hoc analysis, patients with MRD <10-4 by PCR were grouped as having positive but not quantifiable (pbnq) or undetectable disease. RESULTS: A higher proportion of patients with MRD <10-4 had undetectable versus pbnq disease after blinatumomab (day 29) than after HC3 (p = 0.0367). Of the 22 patients with MRD ≥10-4 at baseline who achieved MRD remission after blinatumomab, 20 (91%) achieved MRD <10-4 remission by day 15. Patients treated with blinatumomab had improved EFS and overall survival compared with those treated with HC3 independent of end-of-induction or baseline (end-of-second consolidation) MRD levels. CONCLUSIONS: Blinatumomab was more efficacious than HC3 regardless of MRD status before treatment. These data support the role of blinatumomab in inducing deep MRD remission, negating the poor prognostic value of MRD.

000      
00000naa a2200000 a 4500
001      
bmc22017817
003      
CZ-PrNML
005      
20220804134415.0
007      
ta
008      
220720s2022 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/pbc.29715 $2 doi
035    __
$a (PubMed)35482538
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Locatelli, Franco $u IRCCS Ospedale Pediatrico Bambino Gesù and Sapienza University of Rome, Rome, Italy $1 https://orcid.org/0000000279763654
245    10
$a Blinatumomab overcomes poor prognostic impact of measurable residual disease in pediatric high-risk first relapse B-cell precursor acute lymphoblastic leukemia / $c F. Locatelli, C. Eckert, O. Hrusak, B. Buldini, M. Sartor, G. Zugmaier, Y. Zeng, D. Pilankar, J. Morris, A. von Stackelberg
520    9_
$a BACKGROUND: Blinatumomab, a CD3/CD19 BiTE® (bispecific T cell engager) molecule, was superior to high-risk third course consolidation chemotherapy (HC3) in prolonging event-free survival (EFS) in children with high-risk first relapse B-cell precursor acute lymphoblastic leukemia (B-ALL). Here, we report results from a post hoc measurable residual disease (MRD) analysis of this phase 3 study (NCT02393859). PROCEDURE: Children >28 days and <18 years with high-risk first-relapse B-ALL in cytomorphological complete remission (M1 marrow, <5% blasts) or with M2 marrow (≥5% and <25% blasts) after induction and two cycles of high-risk consolidation chemotherapy (baseline) were enrolled in this trial. Patients received one cycle of blinatumomab (15 μg/m2 /day, 4 weeks, continuous intravenous infusion) or HC3. The primary endpoint was EFS. In this post hoc analysis, patients with MRD <10-4 by PCR were grouped as having positive but not quantifiable (pbnq) or undetectable disease. RESULTS: A higher proportion of patients with MRD <10-4 had undetectable versus pbnq disease after blinatumomab (day 29) than after HC3 (p = 0.0367). Of the 22 patients with MRD ≥10-4 at baseline who achieved MRD remission after blinatumomab, 20 (91%) achieved MRD <10-4 remission by day 15. Patients treated with blinatumomab had improved EFS and overall survival compared with those treated with HC3 independent of end-of-induction or baseline (end-of-second consolidation) MRD levels. CONCLUSIONS: Blinatumomab was more efficacious than HC3 regardless of MRD status before treatment. These data support the role of blinatumomab in inducing deep MRD remission, negating the poor prognostic value of MRD.
650    _2
$a akutní nemoc $7 D000208
650    12
$a protilátky bispecifické $x terapeutické užití $7 D018033
650    12
$a Burkittův lymfom $x farmakoterapie $7 D002051
650    _2
$a dítě $7 D002648
650    _2
$a lidé $7 D006801
650    12
$a B-buněčný lymfom $x farmakoterapie $7 D016393
650    _2
$a reziduální nádor $x chemicky indukované $x farmakoterapie $7 D018365
650    12
$a pre-B-buněčná leukemie $x terapie $7 D015452
650    12
$a akutní lymfatická leukemie $x farmakoterapie $7 D054198
650    _2
$a prognóza $7 D011379
650    _2
$a recidiva $7 D012008
655    _2
$a klinické zkoušky, fáze III $7 D017428
655    _2
$a časopisecké články $7 D016428
700    1_
$a Eckert, Cornelia $u Charite-Universitatsmedizin Berlin, Berlin, Germany $1 https://orcid.org/0000000310392872
700    1_
$a Hrusak, Ondrej $u Charles University, Motol University Hospital, Prague, Czech Republic
700    1_
$a Buldini, Barbara $u Maternal and Child Health Department, University of Padua, Padua, Italy
700    1_
$a Sartor, Mary $u Westmead Hospital, Sydney, New South Wales, Australia
700    1_
$a Zugmaier, Gerhard $u Amgen Research (Munich) GmbH, Munich, Germany $1 https://orcid.org/0000000168792671
700    1_
$a Zeng, Yi $u Amgen Inc., Thousand Oaks, California, USA
700    1_
$a Pilankar, Deepali $u IQVIA, Mumbai, India
700    1_
$a Morris, Joan $u Amgen Inc., Thousand Oaks, California, USA
700    1_
$a von Stackelberg, Arend $u Charite-Universitatsmedizin Berlin, Berlin, Germany
773    0_
$w MED00181047 $t Pediatric blood & cancer $x 1545-5017 $g Roč. 69, č. 8 (2022), s. e29715
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35482538 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220720 $b ABA008
991    __
$a 20220804134408 $b ABA008
999    __
$a ok $b bmc $g 1821760 $s 1169060
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 69 $c 8 $d e29715 $e 20220428 $i 1545-5017 $m Pediatric blood & cancer $n Pediatr Blood Cancer $x MED00181047
LZP    __
$a Pubmed-20220720

Najít záznam

Citační ukazatele

Možnosti archivace